|
1
|
Carlson RW, Anderson BO, Burstein HJ,
Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes
DF, Hudis CA, et al: Invasive breast cancer. J Natl Compr Canc
Netw. 5:246–312. 2007.PubMed/NCBI
|
|
2
|
Cufer T: Reducing the risk of late
recurrence in hormone-responsive breast cancer. Ann Oncol. 18(Suppl
8): viii18–viii25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Greenberg PA, Hortobagyi GN, Smith TL,
Ziegler LD, Frye DK and Buzdar AU: Long-term follow-up of patients
with complete remission following combination chemotherapy for
metastatic breast cancer. J Clin Oncol. 14:2197–2205.
1996.PubMed/NCBI
|
|
4
|
Heldring N, Pike A, Andersson S, Matthews
J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, et
al: Estrogen receptors: How do they signal and what are their
targets. Physiol Rev. 87:905–931. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roger P, Sahla ME, Mäkelä S, Gustafsson
JA, Baldet P and Rochefort H: Decreased expression of estrogen
receptor beta protein in proliferative preinvasive mammary tumors.
Cancer Res. 61:2537–2541. 2001.PubMed/NCBI
|
|
6
|
Zhao M and Ramaswamy B: Mechanisms and
therapeutic advances in the management of endocrine-resistant
breast cancer. World J Clin Oncol. 5:248–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ali S and Coombes RC: Endocrine-responsive
breast cancer and strategies for combating resistance. Nat Rev
Cancer. 2:101–112. 2002. View
Article : Google Scholar
|
|
8
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Osborne CK, Bardou V, Hopp TA, Chamness
GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM and Schiff
R: Role of the estrogen receptor coactivator AIB1 (SRC-3) and
HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer
Inst. 95:353–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kasai M, Guerrero-Santoro J, Friedman R,
Leman ES, Getzenberg RH and DeFranco DB: The Group 3 LIM domain
protein paxillin potentiates androgen receptor transactivation in
prostate cancer cell lines. Cancer Res. 63:4927–4935.
2003.PubMed/NCBI
|
|
11
|
Fujimoto N, Yeh S, Kang HY, Inui S, Chang
HC, Mizokami A and Chang C: Cloning and characterization of
androgen receptor coactivator, ARA55, in human prostate. J Biol
Chem. 274:8316–8321. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sundberg-Smith LJ, DiMichele LA, Sayers
RL, Mack CP and Taylor JM: The LIM protein leupaxin is enriched in
smooth muscle and functions as an serum response factor cofactor to
induce smooth muscle cell gene transcription. Circ Res.
102:1502–1511. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaulfuss S, Grzmil M, Hemmerlein B, Thelen
P, Schweyer S, Neesen J, Bubendorf L, Glass AG, Jarry H, Auber B,
et al: Leupaxin, a novel coactivator of the androgen receptor, is
expressed in prostate cancer and plays a role in adhesion and
invasion of prostate carcinoma cells. Mol Endocrinol. 22:1606–1621.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grzmil M, Kaulfuss S, Thelen P, Hemmerlein
B, Schweyer S, Obenauer S, Kang TW and Burfeind P: Expression and
functional analysis of Bax inhibitor-1 in human breast cancer
cells. J Pathol. 208:340–349. 2006. View Article : Google Scholar
|
|
15
|
Grzmil M, Thelen P, Hemmerlein B, Schweyer
S, Voigt S, Mury D and Burfeind P: Bax inhibitor-1 is overexpressed
in prostate cancer and its specific down-regulation by RNA
interference leads to cell death in human prostate carcinoma cells.
Am J Pathol. 163:543–552. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Renoir JM, Marsaud V and Lazennec G:
Estrogen receptor signaling as a target for novel breast cancer
therapeutics. Biochem Pharmacol. 85:449–465. 2013. View Article : Google Scholar
|
|
17
|
Panousis D, Patsouris E, Lagoudianakis E,
Pappas A, Kyriakidou V, Voulgaris Z, Xepapadakis G, Manouras A,
Athanassiadou AM and Athanassiadou P: The value of TOP2A, EZH2 and
paxillin expression as markers of aggressive breast cancer:
Relationship with other prognostic factors. Eur J Gynaecol Oncol.
32:156–159. 2011.PubMed/NCBI
|
|
18
|
Short SM, Yoder BJ, Tarr SM, Prescott NL,
Laniauskas S, Coleman KA, Downs-Kelly E, Pettay JD, Choueiri TK,
Crowe JP, et al: The expression of the cytoskeletal focal adhesion
protein paxillin in breast cancer correlates with HER2
overexpression and may help predict response to chemotherapy: A
retrospective immunohistochemical study. Breast J. 13:130–139.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Deakin NO and Turner CE: Distinct roles
for paxillin and Hic-5 in regulating breast cancer cell morphology,
invasion, and metastasis. Mol Biol Cell. 22:327–341. 2011.
View Article : Google Scholar :
|
|
20
|
Shibanuma M, Kim-Kaneyama JR, Ishino K,
Sakamoto N, Hishiki T, Yamaguchi K, Mori K, Mashimo J and Nose K:
Hic-5 communicates between focal adhesions and the nucleus through
oxidant-sensitive nuclear export signal. Mol Biol Cell.
14:1158–1171. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong JM, Lau LS, Ng YW, Lim L and Manser
E: Paxillin nuclear-cytoplasmic localization is regulated by
phosphorylation of the LD4 motif: Evidence that nuclear paxillin
promotes cell proliferation. Biochem J. 418:173–184. 2009.
View Article : Google Scholar
|
